GlassScriptPhysician profile
Angeline Falls Derham
NPI 1255795217
$4,183.11
in general payments reported to CMS, 2019-2025
21 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.15 · 2021: $623 · 2022: $929 · 2023: $832 · 2024: $955 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526 · Long Term Medical Supply Or Device Loan: $64.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.55 |
| Long Term Medical Supply Or Device Loan | $64.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.03 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $716.77 | 2021-2025 | Lensx, Argos, Eysuvis |
| Rxsight INC | $449.81 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $391.09 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $348.72 | 2021-2023 | One Series Ultra |
| Allergan, INC. | $190.10 | 2021-2022 | |
| Astellas Pharma US INC | $181.19 | 2024-2025 | Izervay |
| Genentech USA, INC. | $141.42 | 2022 | |
| Horizon Therapeutics Plc | $138.52 | 2022 | |
| Biotissue Holdings INC. | $133.65 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $82.58 | 2020-2025 | |
| Amgen INC. | $74.04 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $64.36 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $64.25 | 2023 | Cirrus Hd-Oct |
| Oyster Point Pharma, INC. | $36.21 | 2022-2024 | Tyrvaya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.96 | 2023 | |
| Rayner Intraocular Lenses Limited | $31.20 | 2023 | Rayone Spheric, Omidria, Rayone Emv |
| Tearlab Corp | $29.74 | 2023 | Tearlab Osmolarity System |
| Glaukos Corporation | $28.84 | 2023 | |
| Aerie Pharmaceuticals, INC. | $24.33 | 2020 | |
| Kala Pharmaceuticals, INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angeline Derham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.